CA
NZ
UK
AU
IND
US
United States Antimony Corporation filed its Form 10-Q for the quarterly period ended June 30, 2026, with the SEC, reporting a net loss of $11,184,200 for the first six months of the year alongside significant balance sheet growth.
Public Policy Holding Company, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, reporting revenue, net loss, and balance sheet figures for the three and six months ended on that date.
Velo3D, Inc. filed a Form 8-K with the SEC on August 11, 2026, announcing the release of its financial results for the three and six months ended June 30, 2026, along with a related earnings presentation and investor conference call.
Revvity, Inc. filed a Form 10-Q with the Securities and Exchange Commission on August 11, 2026, covering the quarterly period ended July 5, 2026, and reporting condensed consolidated financial results for both the three and six months ended on that date.
Savara Inc. filed its quarterly report on Form 10-Q with the SEC on August 11, 2026, covering the three- and six-month periods ended June 30, 2026, disclosing a net loss of $40.2 million for the second quarter and $77.5 million for the first half …
Anteris Technologies Global Corp. filed its Form 10-Q with the SEC for the quarterly period ended June 30, 2026, reporting a net loss attributable to stockholders of $29.094 million for the second quarter and $52.118 million for the first half of the year.
Janus International Group, Inc. filed its quarterly report on Form 10-Q with the SEC on August 11, 2026, covering the fiscal quarter ended July 4, 2026.
Kyverna Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on August 11, 2026, covering the three- and six-month periods ended June 30, 2026.
Erasca, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing a net loss of $227.5 million for the first half of the year, driven largely by a $150.0 million in-process research and development charge.
Taysha Gene Therapies, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission on August 11, 2026, disclosing a net loss of $46.6 million for the second quarter and cash of $455.4 million following …
Please wait processing your request...